BTIG Maintains Buy on Kazia Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the price target from $34 to $40.
BTIG analyst Kambiz Yazdi maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the price target from $34 to $40.